193 Participants Needed

Sacituzumab Govitecan Combo for Lung Cancer

(EVOKE-02 Trial)

Recruiting at 122 trial locations
GC
Overseen ByGilead Clinical Study Information Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications. However, you cannot have received systemic anticancer treatment in the past 6 months, and you should not be on chronic systemic steroid therapy.

What data supports the effectiveness of the drug Sacituzumab Govitecan Combo for Lung Cancer?

Research shows that combining pembrolizumab (an immune therapy drug) with platinum-based chemotherapy, like carboplatin or cisplatin, improves outcomes in advanced non-small cell lung cancer compared to chemotherapy alone. This suggests that adding Sacituzumab Govitecan to a similar combination might also be effective.12345

Is the Sacituzumab Govitecan Combo for Lung Cancer generally safe in humans?

The combination of pembrolizumab with carboplatin and other drugs has been studied for lung cancer, showing that while it can improve survival, it also increases the risk of serious side effects. These side effects can include severe adverse events, which are more common when additional drugs like atezolizumab are added to the treatment.16789

What makes the Sacituzumab Govitecan combo drug unique for lung cancer?

The Sacituzumab Govitecan combo is unique because it combines an antibody-drug conjugate (Sacituzumab Govitecan) with traditional chemotherapy agents (Carboplatin, Cisplatin) and an immunotherapy drug (Pembrolizumab), potentially offering a novel approach by targeting cancer cells directly while also boosting the immune system to fight lung cancer.12101112

Research Team

GS

Gilead Study Director

Principal Investigator

Gilead Sciences

Eligibility Criteria

This trial is for adults with advanced or metastatic non-small-cell lung cancer (NSCLC) who haven't had systemic treatment for it. They should have a good performance status, meaning they can carry out daily activities with little or no assistance. Their blood counts and liver function need to be within certain ranges, and their disease must be measurable on scans.

Inclusion Criteria

My cancer can be measured on scans.
My cancer can be measured on scans according to specific criteria.
I haven't had any systemic treatment for my advanced lung cancer.
See 14 more

Exclusion Criteria

I have an immune system disorder or am on long-term steroids.
I have been treated for an autoimmune disease in the last 2 years.
I haven't had any cancer treatment in the last 6 months.
See 15 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Safety Run-in

Participants receive sacituzumab govitecan at de-escalating dose levels with pembrolizumab and carboplatin or cisplatin to determine the recommended phase 2 dose

21-day cycles
Visits on Days 1 and 8 of each cycle

Treatment

Participants receive sacituzumab govitecan at the recommended phase 2 dose with pembrolizumab and a platinum agent (carboplatin or cisplatin) based on cohort assignment

21-day cycles
Visits on Days 1 and 8 of each cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-8 weeks

Treatment Details

Interventions

  • Carboplatin
  • Cisplatin
  • Pembrolizumab
  • Sacituzumab Govitecan-hziy (SG)
Trial Overview Researchers are testing the drug sacituzumab govitecan-hziy (SG), alone and in combination with pembrolizumab and either carboplatin or cisplatin. The study aims to find effective dosing regimens for patients with NSCLC that has spread beyond its original site.
Participant Groups
7Treatment groups
Experimental Treatment
Group I: Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)Experimental Treatment2 Interventions
Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
Group II: SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)Experimental Treatment3 Interventions
Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m\^2 on Day 1 of a 21-day cycle.
Group III: SG + Pembrolizumab + Cisplatin (Cohort E)Experimental Treatment3 Interventions
Participants assigned to Cohort E will receive SG RP2D, as determined following safety review of Cohorts C and D, on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/ m\^2 on Day 1 of a 21-day cycle.
Group IV: SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)Experimental Treatment4 Interventions
Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
Group V: SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)Experimental Treatment4 Interventions
Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
Group VI: SG + Pembrolizumab + Carboplatin Safety Run-inExperimental Treatment3 Interventions
Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.
Group VII: SG + Pembrolizumab (Cohort B)Experimental Treatment2 Interventions
Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.

Carboplatin is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Paraplatin for:
  • Ovarian cancer
  • Testicular cancer
  • Lung cancer
  • Head and neck cancer
  • Brain cancer
🇪🇺
Approved in European Union as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
🇨🇦
Approved in Canada as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
  • Testicular cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Gilead Sciences

Lead Sponsor

Trials
1,150
Recruited
878,000+
Daniel O'Day profile image

Daniel O'Day

Gilead Sciences

Chief Executive Officer since 2019

MBA from Columbia University

Dietmar Berger profile image

Dietmar Berger

Gilead Sciences

Chief Medical Officer

MD and PhD from Albert-Ludwigs University School of Medicine

Merck Sharp & Dohme LLC

Industry Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Findings from Research

In a real-life study of 121 patients with advanced non-squamous non-small cell lung cancer, the combination of pembrolizumab and chemotherapy resulted in a median progression-free survival of 9 months and overall survival of 20.6 months, demonstrating its efficacy as a first-line treatment.
The treatment was generally well-tolerated, with manageable side effects; however, 17.5% of patients experienced grade 3-4 adverse events, and there were two treatment-related deaths, indicating the need for careful monitoring during therapy.
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).Renaud, E., Ricordel, C., Corre, R., et al.[2023]
In a phase II study involving 167 patients with stage IV squamous non-small-cell lung cancer, the combination of necitumumab with paclitaxel-carboplatin chemotherapy resulted in a higher objective response rate (48.9%) compared to chemotherapy alone (40.0%).
The safety profile of necitumumab was consistent with other EGFR monoclonal antibodies, with increased rates of hypomagnesemia and rash, but overall adverse events were low, indicating that necitumumab can be safely combined with chemotherapy for improved treatment outcomes.
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.Spigel, DR., Luft, A., Depenbrock, H., et al.[2022]
In a pooled analysis of 444 patients with PD-L1-negative advanced/metastatic non-small cell lung cancer (NSCLC), pembrolizumab combined with chemotherapy significantly improved overall survival (hazard ratio 0.63) and progression-free survival (hazard ratio 0.68) compared to chemotherapy alone.
Despite high rates of adverse events (99.2% in the pembrolizumab group), the combination therapy was manageable and resulted in an impressive objective response rate of 87.5% and a 3-year overall survival rate of 100% for patients completing 2 years of treatment.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.Borghaei, H., Langer, CJ., Paz-Ares, L., et al.[2021]

References

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). [2023]
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. [2022]
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. [2021]
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. [2022]
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. [2019]
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. [2023]
Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis. [2022]
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. [2018]
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS). [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. [2015]